Skip to main content
. Author manuscript; available in PMC: 2014 Feb 1.
Published in final edited form as: Cancer Treat Rev. 2012 Aug 13;39(1):97–104. doi: 10.1016/j.ctrv.2012.07.002

Table 5.

Percent Reduction in BTM at 13 weeks. Denosumab vs. Bisphosphonates.

BTM Denosumab
(N)		 Bisphosphonates
(N)		 Pooled Mean
Difference		 95%CI I2 P-value
Denosumab vs. Zoledronic Acid/Pamidronate/Ibandronate a
uNTX a 28,
32-36 		2980 2719 −14.9 −19.2,−10.7 78% <0.0001
BSAP 34-36 2771 2609 −6.5 −8.9,−4.2 13% <0.0001
Denosumab vs. Zoledronic Acid
uNTX 2650 2629 −12.5 −14.8,−10.3 53% 0.001
BSAP 2554 2552 −7.6 −9.9,−5.2 0% <0.0001
a

Insufficient information to analyze data separately for each bisphosphonates.

a

Body et al.,32 reported percent reductions in uNTX for different doses of denosumab (0.1,0.3,1.0,3.0 mg/kg). uNTX, urine N-telopeptide; BSAP, serum bone-specific alkaline phosphatase.